Penumbra (PEN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.20
- Estimate
- $1.21
- Surprise
- -0.3%
- Revenue (period 2026-09-30)
- $410.1M
- Score at report (before → after)
- 4.7 → 4.8/10
Revenue source: xbrl.
How the report landed
Penumbra (PEN) missed the $1.21 estimate with adjusted EPS of $1.20 — effectively in line (0.3%). TrendMatrix's engine moved from Data Issue (4.7/10) to Sell at 4.8/10 after the report — the engine's score rose despite the miss.
Coverage in the report window
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates PEN Sell at 4.7/10.
1 of the last 4 quarters beat the estimate; this quarter's -0.3% surprise compares with a -3.3% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive insider activity
What argues against it
- Concentration risk — Product: thrombectomy products
- Concentration risk — Supplier: single or limited number of suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $320.01
- Stop
- $314.99
The stock trades at 80.6× trailing but 53.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-20 — shown for context, not personalized investment advice.
PEN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $12.61B
- P/E (fwd)
- 53.2
- P/E (ttm)
- 80.6
- 52-week range
- $277.54–$362.41
- Off 52-week high
- 11.7%
- RSI (14)
- 53
- Volume vs avg
- 0.59×
- Score today
- 4.7/10